XOMA Corp
NASDAQ: XOMA · HEALTHCARE · BIOTECHNOLOGY
Updated 2026-04-30
XOMA Corp (XOMA) Stock Valuation Analysis
Fair value estimate, historical valuation range, and quality signals for XOMA.
Valued
Valuation reasonably reflects current fundamentals. Limited margin of safety at these levels.
XOMA historical valuation range
Where current P/E sits in XOMA's own 5Y range.
XOMA intrinsic value (DCF)
DCF-based fair value estimate vs current market price.
Intrinsic value calculated using discounted cash flow (DCF) model based on projected free cash flows, discount rate, and terminal growth assumptions. A positive margin of safety indicates the current price is below estimated fair value, providing a cushion against estimation error.
XOMA valuation signals
Quick-read green flags, caution flags, and risks based on current metrics.
P/E Ratio — History
Current: 25.96x
P/S Ratio — History
Current: 8.66x
Is XOMA overvalued in 2026?
XOMA Corp (XOMA) currently trades at $40.94 per share with a market capitalization of $451,606,000.00. Based on our multi-factor framework, the stock trades at a fair valuation with a Smart Value Score of 52/100. This score blends growth quality, financial health, and price attractiveness into a single institutional-grade read.
The stock trades at a P/E ratio of 26.0x, below its 5-year median of 33.6x.
Looking at its own history, XOMA is currently trading cheaper than 73% of the last 5Y on P/E. This places it in the 27th percentile of its historical range, a reasonable but unremarkable position.
Our discounted cash flow model estimates XOMA's intrinsic value at $24.22 per share, against the current market price of $40.94. This implies a margin of safety of +3.92%. The stock is priced close to its estimated fair value, offering limited upside without further operational improvement.
The Piotroski F-Score of 4/9 puts financial quality in a middling range, neither a standout strength nor an obvious red flag.
Bottom line: XOMA trades at a fair valuation on our framework, with a Smart Value Score of 52/100. The valuation is defensible but offers no obvious bargain. Patience or a better entry price may reward disciplined buyers.
Frequently asked questions
Is XOMA overvalued in 2026?
Based on a Smart Value Score of 52/100, XOMA is fairly valued. Price reasonably reflects current fundamentals with limited cushion in either direction.
What is XOMA's fair value?
Our DCF model estimates XOMA's intrinsic value at $24.22 per share, versus the current price of $40.94. This produces a margin of safety of +3.92%.
What P/E ratio does XOMA trade at?
XOMA trades at a P/E of 26.0x on trailing twelve-month earnings, compared to its 5-year median of 33.6x.
Is XOMA a buy based on valuation?
WallStSmart does not issue buy or sell recommendations. Our Smart Value Score of 52/100 reflects the combined read on growth, quality, and price. The profile is balanced. Best suited for investors with an existing thesis.
How does XOMA's valuation compare to its history?
On P/E, XOMA currently sits in the 27th percentile of its own 5Y range. That is below its long-run median relative to where it has traded over the period.
What is XOMA's Smart Value Score?
XOMA's Smart Value Score is 52/100. The Smart Value Score is a proprietary WallStSmart metric blending growth quality, financial health, and valuation attractiveness into a single 0-100 read. Scores above 75 are rare and indicate strong multi-factor alignment.